Last reviewed · How we verify
NCT05931445
Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer
NA trial testing e-PRO monitoring in Breast Cancer in 500 participants. Participants enrolled and being followed up; not accepting new ones.
31 March 2026
Quick facts
| Lead sponsor | Comprehensive Support Project for Oncology Research |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 500 |
| Start date | 26 January 2021 |
| Primary completion | 31 March 2026 |
| Estimated completion | 31 March 2027 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- e-PRO monitoring
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Lung Cancer — all drugs for Lung Cancer →
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Liver Cancer — all drugs for Liver Cancer →
Sponsor
Comprehensive Support Project for Oncology Research — full company profile →
Who can join
18 and older, any sex, with Breast Cancer or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, open-label, randomized, controlled study to test the hypothesis that ePRO monitoring added to usual care helps prolong OS or maintain and improve HRQoL in patients with unresectable advanced cancers or metastatic/recurrent solid tumors receiving systemic drug therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05931445
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Comprehensive Support Project for Oncology Research trials
Trials by the same sponsor.
- NCT02376985 — Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT · Phase 3 · completed
- NCT01104935 — National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT] · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05931445 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Comprehensive Support Project for Oncology Research
- Last refreshed: 23 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05931445.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing